Is there a need to add another dimension (time) to the evaluation of the arrhythmogenic potential of new drug candidates in vitro?

Circulation

Volumn 130, Issue 3, 2014, Pages 219-220

  Townsend, Claire ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

arrhythmias; cardiac; Editorials; phosphatidylinositol 3 kinase; safety; sodium channels

Indexed keywords

NEW DRUG; SODIUM CHANNEL;

ACTION POTENTIAL; ARRHYTHMOGENESIS; CHANNEL GATING; EDITORIAL; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE EXCITABILITY; HUMAN; IN VITRO STUDY; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SODIUM CURRENT;

ARRHYTHMIAS, CARDIAC; EDITORIALS; PHOSPHATIDYLINOSITOL 3-KINASE; SAFETY; SODIUM CHANNELS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; POTASSIUM CHANNEL BLOCKERS; TORSADES DE POINTES;

EID: 84904571014     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.010819     Document Type: Editorial

References (13)

1. Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 2013;138:470-484.
2. Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T, Holloway C, McMahon N, Milligan J, Park B, Pirmohamed M, Pollard C, Radford J, Roome N, Sager P, Singh S, Suter T, Suter W, Trafford A, Volders P, Wallis R, Weaver R, York M, Valentin J. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011;163:675-693.
3. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals: S7B. Geneva, Switzerland: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Safety/S7B/Step4/S7B-Guideline.pdf. Accessed June 13, 2014.
4. Townsend C, Brown BS. Predicting drug-induced QT prolongation and torsades de pointes: A review of preclinical endpoint measures. Curr Protoc Pharmacol. 2013;61:10.16.1-10.16.19.
5. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. J Cardiovasc Pharmacol. 2004;43:369-379.
6. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
7. Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochem Soc Trans. 2007;35(pt 5):1060-1063.
8. Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, Lin RZ. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012;4:131-50.
9. Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM. Screening for acute IKr block is insufficient to detect torsades de pointes liability: Role of late sodium current. Circulation. 2014;130:224-234.
10. Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, Kramer JW, Yang T, Brown AM. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther. 2008;324:427-433.
11. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167:292-300.
12. Beattie KA, Luscombe C, Williams G, Munoz-Muriedas J, Gavaghan DJ, Cui Y, Mirams GR. Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. J Pharmacol Toxicol Methods. 2013;68:88-96.
13. Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: Implications for drug safety assessment. J Cardiovasc Electrophysiol. 2013;25:197-207.